India’s CERVAVAC Launch: Why This Matters for Cervical Cancer Prevention

Topic: India update

In the landscape of women’s preventive health in India, few announcements have been as significant as the launch of CERVAVAC. Developed by the Serum Institute of India (SII), it is India’s first indigenous quadrivalent Human Papillomavirus (HPV) vaccine.

Why is this huge news? Because it tackles the second most common cancer among women in India—Cervical Cancer—at a price point and scale that makes elimination a real possibility.

The Problem: Cervical Cancer in India

The statistics are sobering. India accounts for nearly one-fifth of the global burden of cervical cancer deaths.

• Every year, over 120,000 Indian women are diagnosed.
• Over 75,000 die from the disease annually.

Unlike many other cancers, cervical cancer is almost entirely preventable because it is caused by a virus: HPV. If you protect against the virus, you protect against the cancer.

What is CERVAVAC?

CERVAVAC is a quadrivalent vaccine, meaning it protects against four strains of HPV:

• Types 16 and 18: These are the high-risk strains responsible for about 70% of all cervical cancers.
• Types 6 and 11: These strains cause genital warts.

Before CERVAVAC, the only options available in India were imported vaccines (like Gardasil or Cervarix), which were often cost-prohibitive for the average family, limiting widespread uptake. CERVAVAC was designed to provide the same efficacy at a fraction of the cost, intended for inclusion in the National Immunization Programme.

Who Should Get It?

The primary target for HPV vaccination is girls aged 9 to 14 years.

• Why this age? The immune response is strongest at this age, often requiring only two doses instead of three.
• Why before 14? The vaccine is preventative, not curative. It works best if administered before exposure to the virus (i.e., before sexual debut).

Can older women take it? Yes. While the public health push focuses on young girls, women up to age 45 can benefit from the vaccine, even if they have been sexually active. It won’t cure an existing HPV infection, but it can protect against the other strains covered by the vaccine. (Consult your gynaecologist for a catch-up schedule, usually 3 doses).

The Path to Elimination

The World Health Organization (WHO) has set a global goal to eliminate cervical cancer as a public health problem. The strategy rests on three pillars (90-70-90):

1. 90% of girls fully vaccinated by age 15.
2. 70% of women screened with a high-performance test by 35 and 45.
3. 90% of women identified with cervical disease receiving treatment.

CERVAVAC is the tool that makes the first pillar achievable for India.

Moving Beyond Stigma

Historically, HPV vaccination in India faced hurdles not just of cost, but of stigma. Because HPV is sexually transmitted, there was hesitation around vaccinating young girls.

We need to shift the narrative. This is not a “sex vaccine”; it is a cancer-prevention vaccine. Just as we vaccinate against Hepatitis B to prevent liver cancer, we vaccinate against HPV to prevent cervical cancer.

With CERVAVAC, India has the technology to save thousands of lives a year. The next step is awareness and acceptance.